NeuBase Therapeutics to Participate in Upcoming Investor Conferences
NeuBase Therapeutics (NASDAQ: NBSE) announces participation in two significant events from December 1-3, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuBase Therapeutics (NASDAQ: NBSE) announces participation in two significant events from December 1-3, 2020. Dietrich A. Stephan, Ph.D., CEO, will engage in a virtual fireside chat at the Piper Sandler Virtual Healthcare Conference and a panel discussion at the Evercore ISI HealthCONx Conference. A webcast of the fireside chat will be available on the Piper Sandler site and NeuBase's website for 90 days post-event. NeuBase focuses on advancing genetic therapies to tackle debilitating diseases using its innovative PATrOL™ technologies.
Details
News Market Reaction – NBSE
The recorded move for NBSE in the trading session of this news was -4.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the 32nd Annual Piper Sandler Virtual Healthcare Conference taking place between December 1-3, 2020, as well as in a panel discussion at the 3rd Annual Evercore ISI HealthCONx Conference, which is also being held from December 1-3, 2020.
A webcast of the Piper Sandler fireside chat will be available on the Piper Sandler conference site from November 23rd to December 3rd. In addition, this webcast will also be available on the NeuBase website, www.neubasetherapeutics.com, for 90 days following the recording of the presentation.
About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576
NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.